DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Geneva, Switzerland and Boston, MA - May 11, 2017 - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that it will report financial results for the first quarter ended March 31, 2017 on Thursday, May 18, 2017. ObsEva will host an investment community conference call at 8:00 a.m. Eastern Time (2:00 p.m. Central European Time) on May 18, 2017 to discuss the financial results and provide a corporate update.
Investors may participate in the conference call by dialing 844-419-1772 for U.S. callers and (213) 660-0921 for international callers, with conference ID: 21002537.
Those interested in listening to the conference call live via the internet may do so by visiting the "Investors" page of ObsEva's website at www.obseva.com and clicking on the webcast link.
A webcast replay of the conference call will be available on the "Investors" page of ObsEva's website at www.obseva.com.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.
###
Media Contact:
Liz Bryan
Spectrum Science
[email protected]
202-955-6222 x2526
Investor Contact:
Mario Corso
Senior Director, Investor Relations
[email protected]
781-366-5726
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/0f853e1e-9419-4a3b-85af-60e6f96631b6
